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Abstract
Background: Atherosclerosis is a systemic, lipid-driven immune-inflammatory disease.
Methods: We retrospectively reviewed institutional electronic medical records to seek chest pain patients who were
suspicious of acute coronary syndrome (ACS) between January 2011 and December 2013. All the patients were identified
by undergoing coronary angiography. On admission white blood cell and its subtypes were measured as part of the
automated complete blood count and fasting venous blood samples were obtained and analyzed for lipids profiles used
automated analysis.
Results: A total of 376 consecutive patients with ACS were investigated. In the same period, 378 patients admitted with
chest pain suspicious of ACS were also included in this study for control. Blood glucose, serum creatinine, white blood
cell, neutrophil and monocyte were insignificantly higher in the ACS group. ACS group had higher total cholesterol and
lower high density lipid-cholesterol. However, triglyceride and low density lipid-cholesterol were similar between ACS and
control groups. Atherogenic index of plasma (AIP) was significantly higher in ACS group compared to control
group (p = 0.029). Similarly, ACS group had higher neutrophil–lymphocyte ratio (NLR) than those in control group.
In the subgroups, the NLR were significantly higher in the STEMI group (p < 0.001). However, AIP were similar
between the three subgroups (p = 0.748).
Conclusions: Our data firstly investigated the lipid-driven inflammatory state in acute coronary syndrome through two
easily feasible parameters. There suggest that there are higher AIP and NLR in the ACS patients. Moreover, ACS
subgroups are all lipid-driven states, but inflammation levels are different in the entity ACS subgroups.
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Background
Coronary heart disease (CHD) is leading cause of morbid-
ity and mortality worldwide [1]. CHD is mainly caused by
coronary atherosclerosis with or without luminal throm-
bosis and vasospasm [2]. Atherosclerosis is a systemic,
lipid-driven immune-inflammatory disease [3]. The func-
tion of inflammation in the development and progression
of atherosclerosis has been clarified [4]. The presence of
inflammation at the site of the atherosclerotic lesion has a
critical pathophysiological role in acute rupture [5].
In recent years, several studies have been demonstrated
that White blood cell (WBC) count and its subtypes are
also known as classic markers of inflammation in cardio-
vascular diseases [6–9]. Palmerini T showed that a high
neutrophil–lymphocyte ratio (NLR) is a strong and in-
dependent predictor of in-hospital cardiovascular mortal-
ity due to ST-segment elevation myocardial infarction
(STEMI) [6].
Dyslipidemia is a well-established risk factor for the
development of atherosclerosis which is lipid-driven
* Correspondence: tanxuerui@vip.sina.com
Department of Cardiology, First Affiliated Hospital of Shantou University
Medical College, Shantou, Guangdong 515041, China
© 2016 Zhan et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zhan et al. BMC Cardiovascular Disorders  (2016) 16:96 
DOI 10.1186/s12872-016-0274-7
disease [10, 11]. The common combined occurrence of
high fasting blood concentrations of triglycerides (TG)
and low levels of high density lipoprotein cholesterol
(HDL-c) has been referred to as atherogenic dyslipid-
emia [12]. Dobiasova and Frohlich have referred to this
log10 [TG/HDL-c] as the atherogenic index of plasma
(AIP) that allows the demonstration of a correlation
with smaller low-density lipoprotein- cholesterol (LDL-c)
particles and increased fractional esterification rate for
cholesterol in plasma [13, 14]. Interestingly, AIP is associ-
ated more strongly with elevated C-reactive protein levels
[12]. However, fewer studies evaluate AIP and classic
markers of inflammation together. There may be links
between NLR and AIP in patients with acute coronary
syndrome (ACS) according to the pathophysiologic of
atherosclerosis, lipid-driven immune-inflammatory dis-
ease [3].
We, therefore, aimed to determine the relationships be-
tween classic markers of inflammation (white blood cell
and its subtypes) and AIP in acute coronary syndrome,
also to evaluate the value the aforementioned parameters
in the differential diagnoses of chest pain patients.
Methods
Study design and definition
We retrospectively reviewed institutional electronic med-
ical records to seek chest pain patients who were suspi-
cious of acute coronary syndrome between January 2011
and December 2013. All the patients were identified by
undergoing coronary angiography. ACS group included
STEMI, non-ST elevated myocardial infarction (NSTEMI)
and unstable angina (UA) that were defined based on the
criteria formulated by updated guidelines [15, 16]. Patients
in the control group were certified the coronary artery nor-
mal by angiography. The chief complaint of all the in-
cluded patients was chest pain. All the patients’ medical
records were reviewed to extract the demographic and
clinical data by two physicians (Youqin Zhan and Tan Xu).
Hypertension was determined if the systolic BP (SBP)
was ≥140 mm Hg and/or the diastolic BP (DBP) was
over 90 mm Hg and/or use of antihypertensive medication
[17]. Individuals with type 2 diabetes were diagnosed
according to the criteria of the American Diabetes As-
sociation, [18] namely when plasma fasting glucose
was more than 7.0 mmol/L (or 2-h postprandial glu-
cose ≥11.1 mmol/L) and/or if there was current use of
diabetes medication.
Patients with clinical evidence of active infection, cancer,
hematological disease, systemic inflammatory conditions,
autoimmune disease, liver disease, and renal failure were
excluded from the study. As well as, patients with a his-
tory of prior myocardial infarction (MI), cerebrovascular
event, peripheral arterial disease, percutaneous coronary
intervention, coronary bypass surgery, and treatment with
anti-platelet or statins were also excluded.
Laboratory analysis
On admission WBC and its subtypes were measured as
part of the automated complete blood count (Beckman
counter LH780, USA). Fasting venous blood samples were
obtained and analyzed for lipids, liver and kidney function
used automated analysis (Beckman counter AU5800,
USA). The NLR and AIP was calculated by EXCEL
(Microsoft Excel). The NLR was calculated as the ratio
of the neutrophils and lymphocytes, both obtained from
the same automated blood sample at admission. AIP was
defined as logarithm of this ratio (TG/HDL-C]) on the
base of 10, which corrects for the lack of normative distri-
bution of the ratio [14].
Statistical analysis
The data were stored using the MS Excel program. The
statistical analysis was carried out using SPSS for Win-
dows release 13.0. Continuous variables are expressed as
means and SD, as counts and percentages for Categorical
variables. The conformity of all parameters to a normal
distribution was tested using the Kolmogorov-Smirnov
test. The independent t test and oneway ANOVA test
were used for continuous variables. The x2 test was per-
formed for the comparison of categorical variables. A
value of p < .05 on the two-sided test was considered
statistically significant.
This study was submitted to and approved by the Re-
search and Ethics Committee of First Affiliated Hospital
of Shantou University Medical College.
Results
Baseline characteristics
In this case-control retrospective study, a total of 376 con-
secutive patients with ACS were investigated. In the same
period, 378 patients admitted with chest pain suspicious
of ACS were also included in this study for control. Com-
parison of clinical and biochemical variables in the ACS
and control groups are shown in Table 1. All the Subjects
hadn’t the history of previous use of statin. The patients in
the ACS group were older than those in the control group.
Body mass index, rate of smoking, history of hypertension
were not different between the ACS and control groups.
Blood glucose, serum creatinine, white blood cell, neutro-
phil and monocyte were insignificantly higher in the ACS
group. On lipid profiles, ACS group had higher total chol-
esterol and lower HDL-c. However, TG and LDL-c were
similar between ACS and control groups.
Lipid-driven inflammatory state-AIP and NLR
All the included patients were suspicious of acute cor-
onary syndrome: lipid-driven inflammatory state. Two
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parameters, AIP and NLR, maybe reflect the state. As
was to be expected, AIP was significantly higher in ACS
group compared to control group (p = 0.029, shown in
Fig. 1a). Similarly, ACS group had higher NLR than
those in control group (p < 0.001, shown in Fig. 1b).
In order to further analyze the lipid-driven inflamma-
tory state in ACS, the ACS groups were divided into
three subgroups, namely, STEMI, NSTEMI and UA
groups. Of the 376 ACS patients included, 237 (63.03 %)
had STEMI, 74 (19.68 %) had NSTEMI and 65 (17.29 %)
had UA. Table 2 shows the baseline characteristic of the
aforementioned three groups. Mean ages, male genders
and body mass index were similar in the three groups
(p = 0.234, p = 0.078 and p = 0.172, respectively). Smoking
was more frequently in the STEMI group (p = 0.033). Rate
of hypertension was higher in the UA groups (p = 0.002).
However, the frequencies of diabetes mellitus were similar
between the three groups (p = 0.194). On the inflamma-
tion profiles, white blood cell, neutrophil and monocyte
were lower in the UA groups than the other two groups
(p < 0.001, p < 0.001 and p = 0.004, respectively). On the
lipid profiles, there were no differences in total cholesterol,
triglyceride, high density lipid-cholesterol and low density
lipid-cholesterol between the three subgroups (p = 0.189,
p = 0.578, p = 0.702, and p = 0.574, respectively). In the
subgroups, the NLR were significantly higher in the
Table 1 Comparison of clinical and biochemical variables in the ACS and control groups
ACS group (n = 376) Control group (n = 378) p value
Age (years) 63.60 ± 11.74 59.81 ± 9.47 <0.001b
Male gender (%) 206 (54.79) 199 (52.65) 0.560a
BMI (kg/m2) 23.51 ± 2.08 22.76 ± 1.18 0.510b
Smoker (%) 250 (66.49) 174 (46.03) 0.070a
History of hypertension (%) 168 (44.68) 184 (48.68) 0.275a
History of diabetes mellitus (%) 84 (22.34) 46 (12.17) <0.001a
SBP (mmHg) 130.99 ± 24.26 136.54 ± 20.48 0.001b
DBP (mmHg) 80.60 ± 14.50 82.54 ± 12.66 0.050b
Blood glucose (mmol/L) 9.23 ± 11.03 5.96 ± 1.84 <0.001b
Serum creatinine (ummol/L) 101.84 ± 38.57 88.17 ± 29.99 <0.001b
WBC (*109/L) 10.83 ± 3.65 7.60 ± 2.49 <0.001b
Neutrophil (*109/L) 7.98 ± 3.44 5.33 ± 10.25 <0.001b
Lymphocyte (*109/L) 1.93 ± 0.92 2.08 ± 0.74 0.016b
Monocyte (*109/L) 0.68 ± 0.33 0.513 ± 0.213 <0.001b
Hemoglobin (g/L) 138.62 ± 66.94 134.27 ± 14.21 0.217b
TC (mmol/L) 5.09 ± 1.30 4.86 ± 1.20 0.015b
TG (mmol/L) 1.62 ± 1.15 1.83 ± 5.13 0.402b
HDL-c (mmol/L) 1.11 ± 0.34 1.24 ± 0.62 <0.001b
LDL-c (mmol/L) 3.31 ± 1.09 3.67 ± 7.37 0.367b
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, WBC white blood cell, TC total cholesterol, TG triglyceride, HDL-c high density
lipid-cholesterol, LDL-c low density lipid-cholesterol. aChi-square test. bIndependent t test
Fig. 1 Comparison AIP (1a), NLR (1b) between the ACS and control groups
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STEMI group (p < 0.001, shown in Fig. 2a). However, AIP
were similar between the three subgroups (p = 0.748,
shown in Fig. 2b).
Discussion
Our data firstly investigated the lipid-driven inflammatory
state in acute coronary syndrome through two easily feas-
ible parameters. Retrospective evaluation of the AIP and
NLR as a lipid and inflammation profiles in ACS patients
yielded the following salient information. The main con-
clusions were that: (i) there were higher AIP and NLR in
the ACS patients compared with other chest pain patients
suspicious of ACS; and (ii) In the ACS subgroups, the
NLR were significantly higher in the STEMI group, how-
ever, AIP were similar.
Regarding lipids profiles in ACS patients, there has
been accumulated several clinical trials to demonstrate
the potential role of lipid in the development of ACS. A
statistically significant association between thrombosis
caused by plaque rupture and high TC, low high-density
lipoprotein cholesterol, and high TC/HDL-C ratio in men
has been evaluated by Burke et al. [19]. In this study, there
found that significantly higher TC and lower HDL-c in
ACS group.
Recently, more studies have been focused on the
parameter-AIP, which is a surrogate of small LDL par-
ticle size. Altan O. et al found that high AIP is a strong
risk factor for CAD in both Turkish men and women
[12]. Similarly, in the present study, AIP also was also
higher in the ACS groups compared with control groups.
Table 2 The baseline characteristic of STEMI, NSTEM and UA groups
STEMI group n = 237 NSTEMI group n = 74 UA group n = 65 p value
Age (years) 62.81 ± 11.45 64.91 ± 13.05 64.98 ± 11.11 0.234b
Male gender (%) 129 (54.43) 39 (52.70) 38 (58.46) 0.078a
BMI (kg/m2) 23.66 ± 1.99 23.16 ± 2.28 23.38 ± 2.22 0.172b
Smoker (%) 169 (71.31) 42 (56.76) 39 (60.00) 0.033a
History of hypertension (%) 90 (37.97) 39 (52.70) 39 (60.00) 0.002a
History of diabetes mellitus (%) 48 (20.25) 16 (21.62) 20 (30.77) 0.194a
SBP (mmHg) 127.07 ± 21.54 134.45 ± 30.66 141.34 ± 22.07 <0.001b
DBP (mmHg) 79.00 ± 13.49 82.42 ± 17.48 84.37 ± 13.53 0.014b
Blood glucose (mmol/L) 9.94 ± 13.60 8.55 ± 3.33 7.40 ± 3.57 0.218b
Serum creatinine (ummol/L) 101.50 ± 37.56 104.78 ± 43.93 99.75 ± 36.06 0.727b
WBC (*109/L) 11.45 ± 3.56 11.14 ± 3.82 8.16 ± 2.43 <0.001b
Neutrophil (*109/L) 8.63 ± 3.35 8.18 ± 3.60 5.32 ± 2.15 <0.001b
Lymphocyte (*109/L) 1.88 ± 0.94 1.98 ± 0.94 2.07 ± 0.81 0.302b
Monocyte (*109/L) 0.70 ± 0.34 0.74 ± 0.38 0.56 ± 0.24 0.004b
Hemoglobin (g/L) 136.67 ± 16.70 150.49 ± 147.18 132.13 ± 15.24 0.210b
TC (mmol/L) 5.14 ± 1.29 5.08 ± 1.27 4.92 ± 1.35 0.189b
TG (mmol/L) 1.59 ± 1.12 1.75 ± 1.39 1.59 ± 0.94 0.578b
HDL-c (mmol/L) 1.11 ± 0.31 1.14 ± 0.47 1.10 ± 0.27 0.702b
LDL-c (mmol/L) 3.36 ± 1.07 3.24 ± 1.14 3.23 ± 1.08 0.574b
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, WBC white blood cell, TC total cholesterol, TG triglyceride, HDL-c high density
lipid-cholesterol, LDL-c low density lipid-cholesterol. aChi-square test. boneway ANOVA test
Fig. 2 Comparison AIP (2a), NLR (2b) between the ACS subgroups
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However, between the subgroups of ACS, there were no
difference in TC, HDL-c and AIP, which may reflects
the coherence of ACS subgroups. Otherwise, a recent
study [20] showed that the TC/HDL ratio was a marker
of severity of CAD in relation to the number of vessels
affected in patients with ACS without ST-segment
elevation.
On the inflammation of ACS, it has been shown to play
a role in the pathogenesis of coronary atherosclerosis [21].
In recent years, higher white blood cell [22] (WBC), and
neutrophil [23, 24], have been evaluated to be associated
with ACS. It has been shown that elevated baseline WBC
count was associated with higher short-term mortality in
UA and NSTEMI [25]. A recent study [22] presented that
WBC was strongly associated with CHD. In terms of
neutrophil, more studies described that elevated neutro-
phil may predict worse outcomes, such as chronic heart
failure, [24] cardiogenic death [23]. Our study shows that
a significantly higher WBC and neutrophil in the ACS
group, and there also exists significantly differences in
WBC and neutrophil between the ACS subgroups.
Moreover, NLR was introduced as a potential marker
to determine inflammation in cardiac disorder and shown
as a predictor of long-term mortality in ACS patients
[26, 27]. Ramazan C. O. et al reported that NLR was
significantly associated with adverse in-hospital outcomes,
independent of GRACE risk score in STEMI patients. In
the present study, ACS patients also had higher NLR
compared to angiographic normal patients. Moreover, the
NLR had significant differences in the ACS subgroups,
highest in the STEMI subgroup.
The most challenging finding of the present study was
to demonstrate the lipid-driven inflammation state in
ACS patients used two combination parameters- AIP
and NLR. To the best of our knowledge, no studies have
assessed the potential role of AIP and NLR together in
ACS patients to evaluate the lipid-driven inflammation
state. Unlikely many other marker and bioassays, AIP
and NLR are inexpensive and readily available markers
that provides an additional level of risk scores in predict-
ing short and long term outcomes in ACS patients. In
this study, there are differences of AIP and NLR between
ACS and control groups. However, in the ACS subgroups,
although no difference found in AIP, yet there were differ-
ences in NLR. In the view of above differences, there may
interpret as the following in leading pathological terms.
Firstly, ACS is a systemic, lipid-driven inflammatory
disease. Therefore, compared to angiographic normal
patients, ACS groups had higher AIP and NLR, which
reflect the lipid and inflammation status. Secondly, in
the ACS groups, there are all lipid-driven states, so
there is no difference in AIP. However, there may be
different inflammation levels in the ACS groups. Lastly,
coincidence may exist in the differences.
Study limitations
The present study must be interpreted within the context
of its potential limitations. First, this was a retrospective
and single-center pilot study. Further prospective multi-
center studies with a larger sample size may be needed.
Second, the patients in NSTEMI and UA subgroups were
smaller compared with the STEMI subgroups which may
disturb the results. Third, we could not compare AIP and
NLR with other lipid and inflammatory markers, because
they were not routinely assessed in our study population.
Conclusion
Our data suggest that there are higher AIP and NLR in
the ACS patients, which evaluate the lipid-driven inflam-
mation state, used two inexpensive parameters. Moreover,
ACS subgroups are all lipid-driven states, but inflamma-
tion levels are different in the entity ACS subgroups. One
challenge of the study is that we firstly evaluate the lipid-
driven inflammation state of ACS used two ratio parame-
ters together, AIP and NLR. Further studies are required
to confirm the clinical relevance of these findings by
comparing the association of AIP and NLR together
with clinical outcomes.
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